
A combination of chemotherapy and immunotherapy may slow the progress of metastatic bladder cancer and extend survival, a clinical trial suggests. Current treatment for advanced bladder cancer is chemotherapy, but adding the immunotherapy drug atezolizumab (Tecentriq) appears to help more patients fight this disease. It strikes 81,000 Americans a year and kills 18,000. “This is… read on >